Summary: An attempt has been made to review the nonlinearities in the disposition in vitro, in situ, in loci and in vivo mainly from a theoretical point of view. Parallel Michaelis-Menten and linear (ˆrst-order) eliminations are often observed in the cellular uptake, metabolism and eOEux of drugs. The well-stirred and parallel-tube models are mainly adopted under steady-state conditions in perfusion experiments, whereas distribution, tank-in-series and dispersion models are often used under nonsteady-state conditions with a pulse input. The analysis of the nonlinear local disposition in loci is reviewed from two points of view, namely an indirect method involving physiologically based pharmacokinetics (PBPK) and a direct (two or three samplings) method using live animals. The nonlinear global pharmacokinetics in vivo is reviewed with regard to absorption, elimination (metabolism and excretion) and distribution.
Introduction
Many drugs administered into the systemic circulation are eliminated by enzymes and transporters expressed mainly in the intestine, liver and kidney, and the drugs bind to proteins in the blood and tissues. The drugs for oral dose can accessibly or restrictively be absorbed by the transporters and enzymes on the intestinal mucosa from the intestine into the portal system. Since the numbers of enzymes, transporters and binding proteins are limited, the disposition of the drugs is possibly capacity-limited, that is, nonlinear. Ethanol is the representative substance that disappears from the body according to nonlinear kinetics which is best described by the Michaelis-Menten (M-M) equation 1) rather than zero-order elimination.
2)
VddC W dt＝-VmaxC W ( Km＋C )
where Vd is distribution volume, dC W dt is rate of concentration change, C is concentration, Vmax is maximum elimination rate, and K m is Michaelis-Menten constant. The coe‹cient Vmax W ( Km＋C ) represents the capacity-limited clearance. It is noted that Eq. (1) is slightly modiˆed compared with the form in the original paper (VddC W dtºdC W dt). M-M equation is reduced approximately either to aˆrst-order (V d dC W dt＝-V max W Km･C for C9Km) or to a zero-order (VddC W dt＝-Vmax for C:Km) form. The use of the integrated form of Eq.
(1) has also been proposed.
3)
C0-C＋Km･ ln (C0 W C )＝(Vmax W Vd)t
where C0 (＝D W Vd) is initial concentration. In this paper, an attempt has been made to review the analytical techniques and the recent advancement in the nonlinear pharmacokinetics from in vitro through in situ and in loci into in vivo, mainly from the standpoint of nonlinear kinetic theory and parameter estimation.
In Vitro
Today, animal and human cells have often been used to investigate the elimination kinetics of drugs in many papers, in addition to the use of homogenates of organ tissues. The cellular uptake of a drug is usually represented by M-M plus linear elimination model. 4) [
where 
In Situ
An organ perfusion experiment is the main method for evaluating the local disposition in organs such as the intestine, liver, kidney and brain. Independently of linear or nonlinear systems, the well-stirred 6, 7) and parallel-tube models 8, 9) have been adopted to estimate drug elimination in perfusion experiments under steadystate conditions, whereas the distributed, 10, 11) tank-inseries 12, 13) and dispersion 14, 15) models have been adopted to well explain the time proˆles under the nonsteady state conditions. Steady-state conditions: For the capacity-limited well-stirred model, 16, 17) Vd dfuCout dt
where Vd is distribution volume, Cin and Cout are concentrations at inlet and outlet of an organ i, respectively, Qi is ‰ow rate of perfusate through organ i, and f u is unbound fraction. fuCout is assumed to be the concentration in the tissue (C ). When the perfusate contains no protein, fu becomes unity. From Eq. (5), the following linear relationship is derived.
Equation (6) 
where [is unitless local volume which corresponds to position in organ. From Eq. (7), the following linear relationship can be derived.
Equation (8) 19, 20) tank-inseries 21) and dispersion models, [22] [23] [24] there is no simple relationship between Cin and Cout such as those shown in Eqs. (6) and (8) . By plotting Eq. (6) or (8) , it is possible in the nonlinear system to determine which model is most suitable, the well-stirred or the parallel model, whereas this distinction is impossible in the linear system.
Nonsteady-state conditions: It was found that about 50z of salicylate disappeared from the liver under nonsteady-state conditions after a pulse input, in spite of the fact that salicylate is not generally eliminated in the liver under steady-state conditions. 25) From the perfusion experiment using 14 C-salicylate, the authors concluded that the hepatic elimination under nonsteadystate conditions is caused by the semi-irreversible binding of salicylate to the hepatic tissues.
The distributed model with Michaelis-Menten uptake was adopted to analyze the nonlinear local disposition of serotonin in the isolated lung. 26) A discrepancy was noticed between the experimental points and predicted lines in the elution of serotonin, which, the authors suggested, is caused by an absence of returning ‰ux of serotonin in their model. The dispersion (mixing or eŠective diŠusion) phenomenon was not included in the distributed model, and this may be why there is no eŠective explanation of local serotonin disposition in the lung.
The tank-in-series model, expressed by simultaneous ordinary diŠerential equations, implicitly evaluates the dispersion phenomenon by N (number of tanks in series). The larger the value of N, the lower the degree of dispersion (mixing through an organ).
Eight tank-in-series models have been compared and their kinetic properties have been discussed. 27) The tankin-series with M-M elimination was applied to analyzing the nonlinear local disposition of oxacillin through the perfused rat liver following a pulse injection. 28) It was found that the out‰ow time-courses of oxacillin were well expressed by two-compartment tank-in-series model with M-M elimination from the central compartment. It is noted that the models from the central and peripheral elimination are kinetically distinguishable in the nonlinear system, whereas it is impossible to distinguish between the central and pheripheral eliminations in the linear system. The tank-in-series model, however, incompletely expresses the dispersion in an organ, because N (number of tanks in series) is restricted to natural number.
The dispersion model, which is represented by second order partial diŠerential equations, explicitly evaluates the dispersion phenomenon by De (eŠective diŠusion coe‹cient) or DN (dispersion number). The properties and the numerical solutions of a nonlinear dispersion model have been discussed from the theoretical point of view.
29) The capacity-limited local disposition of cyclopentapeptide, BQ-123, was analyzed by the nonlinear dispersion model, using perfused rats liver under nonsteady-state conditions. 30, 31) A dose-dependence in the renal disposition of p-aminohippurate was reported after an instantaneous bolus injection of inulin (an extravascular reference marker) into the perfused rat kidney using the dispersion model with M-M elimination.
32) The predicted curves are in good agreement with the experimental points describing the urinary excretion. Oxacillin and 5-‰uorouracil were selected as model drugs to demonstrate the nonlinear hepatic elimination in hepatic perfusion experiments under nonsteady-state conditions using rats. 33, 34) The hepatic recovery ratio ( F H ) and the mean hepatic transit time (tH) are deˆned by Eqs. (9) and (10), respectively, in the perfusion experiment. 35 )
where QH is perfusate ‰ow rate through the liver, C (t ) is concentration time course eluted from the liver, and D is dose administered to the liver. FH of both model drugs were increased to unity with an increase in the dose into the liver. The mean transit timetH of 5-‰uorouracil was rapidly increased with an increase in the dose, whereast H of oxacillin remained almost constant, exhibiting only a slight increase. The local time-courses of oxacillin or 5-‰uorouracil on changing the administered dose were simultaneouslŷ tted on the dispersion model with M-M elimination. Based on Akaike's information criterion (AIC), 36) the hepatic disposition of 5-‰uorouracil was well described by two-compartment dispersion model with M-M elimination from the peripheral compartment, whereas that of oxacillin from the central compartment. The dose dependence int H shows whether the nonlinear elimination is from the central or peripheral site. The dosedependence in the hepatobilliary transport of cefpiramide was assessed on a hepatocellular diŠusion model with capacity-limited permeation across the bile canalicular membrane. 37) Using AIC, cefpiramide was found to be eliminated from the perfusate by two-compartment dispersion model with central M-M elimination, whereas cefpiramide was excreted into the bile by capacity-limited transport through the canalicular membrane. It has been reported that a transporter MRP2 W cMOAT is expressed in the canalicular membrane and cefpiramide is a substrate of this transporter. 38, 39) The capacity-limited biliary excretion of cefpiramide is predicted to be caused by saturation of the MRP2 W cMOAT transport system. The dispersion model with M-M elimination is useful to quantitatively evaluate capacity-limited local disposition involving enzymes and transporters in the liver and kidney elimination, and possibly nonlinear absorption from the intestine into the portal system.
In Loci
The terms``in situ'' and``in locus'' both mean``in place'' or``in site'', and loci is the plural of locus. Thus, the drug disposition in loci means the global disposition that consists of the local disposition in several organs and anatomical sites of an animal.
Indirect method: Physiologically based pharmacokinetics (PBPK) is extensively used for analyzing drug disposition following the progressive increase in computer power. We are able toˆnd about 200 papers on PBPK using MEDLINE over the period 2000-2004, which represents more than 50 papers per year. PBPK was reviewed with regard to three points, that is, model development, implementation, and current limitations and future possibilities, making reference to about 300 papers. 40 ) PBPK models are usually described by simultaneous ordinary diŠerential equations, whereas the signal ‰ow analysis using transfer function (the Laplace transformed function) can be applied to PBPK when the model system is linear.
The disposition of cyclosporine A has been evaluated by PBPK, incorporating capacity-limited distribution and nonlinear elimination. 41) The capacity-limited distribution of cyclosporine A was noticed in many organs (linear: muscle and fat; instantaneous saturation: lung, heart, bone, skin and thymus; non-instantaneous saturation: kidney, spleen, liver and gut; saturable eOEux: brain), whereas no nonlinearity in elimination (hepatic clearance) was observed. The simpliˆcation (reduction and lumping) of a complicated PBPK model has been attempted using fentanyl and pethidine as model drugs. 42) Successively, the predicted time courses were in good agreement with the experimental data points, which shows that several organs can be lumped into one site.
The dose-dependency of allometric scaling for 12 substances was attempted to be theoretically explained by means of PBPK modeling, considering the capacitylimited elimination. All PBPK models were constructed considering M-M kinetics in a computer language ACSL The human equivalent dose (HED) was deˆned by Eq. (11). 43) HED＝AD･( BWA W BWH) X-SF (11) where AD is animal dose, BWA and BWH are body weights of animal and human, respectively, and SF is scaling factor (unitless). X＝1 if SF is positive and X＝-1 if SF is negative. It is interesting that SF takes values of 0.66(＝2 W 3), 0.75(＝3 W 4) or 1.0 depending on the substance. It is noted that 0.66 or 0.75 is proportional to the surface area of animals and 1.0 to the volume.
Direct method: This method is called``in loci'' in a narrow deˆnition. The blood concentration of a drug is usually the same in the systemic circulation (artery and vein), except for three sites. The concentrations in the portal, hepatic and renal veins (Cpor, Chep and Cren, respectively) may be diŠerent from that in the systemic circulation (Csys). Therefore, if Cpor, Chep Cren and Csys of the drug are simultaneously measured, it is expected that the local disposition from the intestine into the portal vein, through the liver and kidney can be estimated from one animal alive. These three organs are the main ones involved in drug elimination from the body.
The hepatic elimination of pravastatin under steadystate conditions was evaluated by measuring the plasma concentration in both arterial and hepatic venous blood in a single live rat.
44) The hepatic recovery ratio ( F H ＝C hep W C sys ) determined directly was reduced with an increase in Csys. The nonlinearly in the hepatic elimination was analyzed based on well-stirred, parallel-tube and dispersion models to estimate the dose-dependence of the hepatic elimination rate. The authors recommend the use of the dispersion model, though that equation appears to be derived under a linear assumption.
The blood concentrations of 5-‰uorouracil were measured simultaneously in an artery, portal and hepatic veins (three points sampling). 45) Assuming that the transient diŠerence ( DC ) in the drug concentration is zero for a short time interval ( Dt ) in the liver (i.e. pseudsteady-state conditions), Eq. (12) can be derived from the nonlinear well-stirred model. This concept is based on the rectangular approximation of Cin(t ) and C out (t ) to C in,i and C out,i (i＝1 to n), respectively, where n is number of sampling points.
where VH is volume of hepatic tissues, QH is hepatic blood ‰ow rate, RB is blood to plasma concentration ratio, fu is free fraction in plasma, CL int is linear portion of intrinsic clearance, and C in and C out are inlet and outlet plasma concentrations of the liver, respectively. The coe‹cient Vmax W ( Km＋fuCout) corresponds to the nonlinear portion of intrinsic clearance. The inlet concentration Cin is strictly deˆned by the ‰ow weighted average, and given by Cin＝ QporCpor＋QhaCsys Qpor＋Qha (13) where Q is blood ‰ow rate, C is concentration, and subscripts por, ha and sys refer to portal, hepatic arterial and systemic concentrations, respectively. Since Qpor is about 4 times larger than Qha, Qha may be neglected. 46) . Also if the concentration diŠerence between Cpor and Csys is negligible in the case of intravenous administration or negligible intestinal absorption, Cin becomes Csys. By solving Eq. (12) with respect to Cout and dividing by Cin,
where
Since Q H and R B are known in Eq. (14), the three unknown parameters Km W fu, Vmax and fuCL int can be estimated by nonlinear least squares for the plots of FH versus Cin. If fu is known, Km and C int can also be estimated. When Cin and Cout approach zero, Eq. (14) becomes
When Cin and Cout are large,
If CL int is negligible, it is simply known Eq. (16) becomes unity.
Total clearance (CL) and mean residence time ( MRT ) in the linear system are given simply by 47) CL＝D W AUC and MRT＝ f / 0 tCsys(t )dt W AUC (17) Let us now consider the case where CL depends on C sys in the nonlinear elimination. CL is originally deˆned by dX W dt＝CL・Csys where dX W dt is the change in the amount of drug in the whole body. By integrating the equation,
By dividing Eq. (18) by AUC,
Csys(t )dt (19)
Equation (19) in the nonlinear system is apparently the same as Eq. (17) in the linear system. CL is called mean total clearance from a statistical standpoint. 48, 49) From the molecular statistics, MRTNL is originally deˆned by
When CL is constant, Eq. (20) is reduced to Eq. (17) . MRTNL deˆned by Eq. (20) becomes greater than MRT by Eq. (17) in the nonlinear elimination system.
49)
The bioavailability F is given by FaFH in the linear system, where Fa is local absorption ratio from the intestine into the portal system and FH is hepatic recovery ratio following a single pass through the liver. F is given by the ratio of AUC after oral dose to that after intravenous dose in the linear system. Fa is evaluated by sampling the portal blood, and the analysis method is mentioned below. FH changes depending on the concentration and time in the capacity-limited hepatic elimination. Fa is estimated by Eq. (21) in the nonlinear system. where dA W dt is absorption rate into the portal system, superscript or subscript po speciˆes oral administration, Csys(t ) and Cpor(t ) are concentrations in the systemic blood and portal vein, respectively, and Qpor is portal blood ‰ow rate. The bioavailability F is estimated by Eq. (22) in the nonlinear hepaticˆrst-pass eŠect.
QporFH(t )･(Cpor(t )-Csys(t ))dt
It was shown in the nonlinear elimination that the ratio F W Fa is given by 50) (23) where Cin(t ) is inlet concentration deˆned by Eq. (13), and superscript po specify oral dose.
FH is called mean hepatic extraction ratio from a statistical standpoint. It should be noted here that C po in (t ), C po sys (t ) and C po por (t ) are all diŠerent at a time t.
The mean hepatic clearance is deˆned by Eq. (24) from a statistical standpoint.
Consequently, CLH is given by QHRB(1-FH) in the nonlinear system, which apparently agrees with that in the linear system. Many drugs are eliminated mainly by the liver and kidney. (25) where CL, CLH and CLR are total, hepatic and renal clearances, respectively, which are dependent on Csys, consequently, on time t. By multiplying Eq. (25), with Csys integrating with time and dividing by AUC,
CL(Csys(t ))＝CLH(Csys(t ))＋CLR(Csys(t ))
That is,
CLR＝CL-CLH (27)
CL, CLH and CLR are called mean clearances. Using Eqs. (19) , (24) and (27) , the mean renal clearance CLR can be estimated. From Eq. (26), Eq. (28) can also be derived.
where D is dose, and XH and XR are amounts of drug eliminated by the liver and kidney, respectively. Equation (28) demonstrates that CL, CLH and CLR are actually proportional to the amount of drug eliminated by the total body ( D), liver ( XH) and kidney ( XR), respectively, in the nonlinear elimination system. Etoposide, an anticancer drug, is known to be a substrate of Pgp 52) and Cyp3A4 which are also expressed in the intestinal wall. 53) Despite the substrate of the enzyme and transporter, the concentration diŠer-ence of etoposide was not observed between the systemic and portal blood after intravenous administration. There are many layers between the epithelium and portal vein, which are predicted to make a barrier blocking the reverse movement of etoposide from the portal vein to the GI tract. Therefore, etoposide is not aŠected by Pgp and Cyp3A4 after intravenous administration, even though those proteins eŠectively block the absorption of etoposide after oral dose. The total clearance CL of etoposide was reduced with an increase in the dose 51) indicating nonlinear elimination. Because CLH calculated from Eq. (24) was almost independent of dose, this shows that the dose-dependence of CL is due mainly to that of CLR.
The enterohepatic circulation, absorption and disposition of cephradine 54) and cipro‰oxacin 55) have been analyzed as a linear system by simultaneously sampling the portal and systemic blood, and expanding the recirculatory model.
In Vivo
Theˆnal aim of pharmacokinetics is to rationally understand and predict the global disposition of drugs and to promote a better use of drugs in clinical situations. The term``in vivo'' is used here to indicate the global disposition that does not explicitly assume the local disposition of drugs in actual organs or anatomical sites. It still remains that the global disposition in vivo should be understood in relation to the local disposition in vitro and in loci. Nonlinearity in global disposition has been reported for the absorption, elimination and distribution.
Absorption: One of the active constituents of Onpito, a herbal medicine, was increasingly absorbed with an increase in the oral dose.
56) The authors concluded that this nonlinear absorption is attributed to saturation of theˆrst-pass eŠect in the intestinal micro‰ora or the liver, which can be simply determined by an in loci experiment. Oral absorption models which are timedependent have been proposed to explain irregular absorption proˆles from the intestine. 57) As shown by Eq. (25) , nonlinear pharmacokinetic models are also time-dependent. Propranolol which exhibits nonlinear kinetics in humans has been used as a model drug, and it was shown that the absorption time-proˆle was well represented by two time-dependent absorption models. The authors insist that the time-dependent models are applicable to the nonlinear pharmacokinetics Elimination: The nonlinear disposition of 5-‰uorouracil has been quantitatively determined based on two-compartment model with parallel M-M and linear eliminations. 58) where Csys and Ct are concentrations in plasma of the
Csys-CLR･Csys-CLD･Csys
systemic circulation and in the tissues, respectively, Vc and Vt are volumes of central and peripheral compartments, respectively, CLR and CLD are renal and distribution clearances, respectively, and Km and Vmax are Michaelis-Menten constants. The term Vmax W (Km＋Csys) represents nonlinear hepatic clearance, whereas CLR is linear renal clearance. The pharmacokinetic parameters were estimated by simultaneous curveˆtting at diŠerent doses (10, 50 and 100 mg W kg). The recent advances in molecular biology and biotechnology have allowed many potent therapeutic proteins to be produced. Those proteins are mainly eliminated by the receptor-mediated endocytosis followed by internalization and degradation, which are likely to be capacity-limited. A general pharmacokinetic model has been proposed for the drugs and proteins that target to enzymes, receptors or transporters. 59) Erythropoietin, which is one of those proteins, was found to be eliminated according to Michaelis-Menten kinetics in newborn sheep and preterm infant. 60, 61) In the analysis of erythropoietin disposition, it was assumed that nonlinearity in the drug disposition is due to nonlinear elimination and that the distribution kinetics is linear. Vmax of lambs were greater than those of neonates, whereas Km were almost the same between two groups. The plasma volume is approximately 4.5z of the body weight. The distribution volume of the central compartment (V c ) was about twice the plasma volume, and the volume at steady state (Vss) was close to the extracellular water volume, indicating that erythropoietin penetrates outside the blood vessels. An endothelial growth factor, which was generated by the recombinant technology, was shown to be eliminated from patients with colonary artery disease in a capacitylimited manner, involving receptor-mediated endocytosis.
62)
Distribution: In contrast to the nonlinear elimination, the total clearance (CL) and the volume of distribution at steady-state (Vss) of ertapenem, a compound which is highly bound to plasma protein, were both increased with an increase in the dose. 63) This phenomenon was explained by nonlinear protein binding. Actually, the free fraction of ertapenem was increased from 5z to 8z with an increase in the plasma concentration from less than 50 mg W mL to 150 mg W mL. The serum kinetics of mefepristone is regulated by a serum protein, a1-acid glycoprotein. 64) It was found that the binding of mefepristone with a1-acid glycoprotein was reduced with an increase in the serum concentration. A relatively marked convulsant antagonism was noticed between nor‰oxacin and theophylline at doses, in spite that there was no interaction in the plasma (extra-biophase), using isobolographic plots. 65) Actually, the convulsant antagonism was detected in the cerebrospinal ‰uid (biophase). This contradiction was explained by the fact that the distribution of nor‰oxacin is capacity-limited between the cerebrospinal ‰uid and the plasma, whereas that of theophylline is linear. CL and Vss of buprenorphine and an active metabolite of roxiˆban, XV459, were increased with an increase in the dose, 66, 67) which is the same as ertapenem. 63) This phenomena were explained that the free fractions of buprenorphine and XV459 were increased in the plasma with an increase in the plasma concentration.
Conclusion
The purpose of pharmacokinetics is to predict the statistical behavior of numerous drug molecules in the body, based on the concentrations in a variety of anatomical sites. There is a simple relationship between the concentrations and the changes in amounts (numbers of molecules) in the linear system. Unfortunately, drugs are usually metabolized and transferred by enzymes and transporters, respectively, which are expressed mainly in the intestine, liver and kidney. Drugs also bind to proteins in the blood and tissues. Protein and gene-based drugs have been developed following the recent advances in molecular biology and biotechnology. Potent proteins generated from those drugs are eliminated by receptor-mediated endocytosis in addition to the degradation in the blood and anatomical sites. Since the numbers of enzymes, transporters, binding proteins and receptors are limited, the drug disposition is possibly capacity-limited. We have tried to review the nonlinear disposition of drugs under a variety of conditions, from in vitro through in loci to in vivo. Drugs are administered to patients mainly to treat physical disorders. The global disposition is the sum of the local disposition at numerous sites in the body, and the local disposition is also the sum of the micro-disposition in the cells. To understand the disposition in vivo and to use drugs more eŠectively in clinical situations, a better understanding of the disposition in vitro and in loci is indispensable.
